Blog Posts

Lilly Says 340B Entities Can’t Designate Central Fill Pharmacies as Contract Pharmacies

Lilly wordmark on top of building
Lilly updated its restrictions on 340B pricing to disallow covered entities from designating central fill pharmacies as contract pharmacies.

Drug manufacturer Eli Lilly late last month again updated its conditions on 340B pricing when covered entities use contract pharmacies.

Lilly was the first company to impose such conditions, starting with one drug in July 2020 then

Read More »

PhRMA Takes its Fight Against Arkansas 340B Law to Federal Appeals Court

U.S. Eighth Circuit Court of Appeals building
PhRMA has asked the federal appeals court in St. Louis to overturn a lower court's ruling that federal law does not preempt Arkansas’s novel 340B anti-discrimination law.

Brand drug manufacturers have asked a federal appeals court to overturn a judge’s ruling last month that Arkansas’s novel 340B anti-discrimination law is not preempted by the 340B statute nor by the U.S. Food and Drug Administration’s Risk

Read More »

Alcon Providing Refunds for 340B Overcharges on 22 Products

Alcon wordmark on a building
Alcon is providing refunds for charges above 340B ceiling prices on 22 NDCs for varying sales periods from Q3 2019 through Q3 2022.

Swiss eye care drug manufacturer Alcon is providing refunds for charges above 340B ceiling prices on 22 NDCs for varying sales periods from Q3 2019 through Q3 2022.

The U.S. Health Resources and Services Administration posted Alcon’s public

Read More »

House GOP Leadership Spat Stymies All Action, Including Any on 340B

Rep. Kevin McCarthy (R-CA) pictured at the entrance to the West Wing of the White House
The split among House Republicans about whether to pick Rep. Kevin McCarthy (Calif.) to be House Speaker has ground the chamber to a halt.

The U.S. House was frozen stuck this morning after the new Republican majority splintered yesterday, the first day of the 118th Congress, over who should be the next House speaker.

Representatives cannot be sworn in and the House

Read More »

Office of Pharmacy Affairs Get Slight Funding Bump

HRSA building and signage
HRSA's Office of Pharmacy Affairs, the unit that oversees the 340B program, will get $12.2 million this fiscal year—$1 million more than last year.

President Biden on Dec. 29 signed a $1.7 trillion omnibus appropriations bill for fiscal year 2023 that gave the 340B drug pricing program a slight funding boost.

The U.S. Health Resources and Services Administration’s Office of Pharmacy Affairs

Read More »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

×

*Sign up for news summaries and alerts from 340B Report

Site Footer